By Connor Hart
Shares of Acurx Pharmaceuticals fell to their lowest price in over a year after the company disclosed a large investment in bitcoin.
The stock slid 17%, to $1.38, in afternoon trading Wednesday and is down 64% since the beginning of the year.
The New York biopharmaceutical company before the bell said its board approved the purchase of up to $1 million in bitcoin to hold as a treasury reserve asset.
"As demand for bitcoin grows, and so does its acceptance as a major and primary asset class, we believe that bitcoin will serve as a strong treasury reserve asset for cash not needed over the next 12-to-18 months," Chief Executive David Luci said.
He added that the company's new finance strategy would have no effect on its overarching drug-development plans.
Bitcoin has soared to record highs since the election, boosted by President-elect Donald Trump's pro-crypto stance, anticipation of a more crypto-friendly regulatory environment under his administration and the election to Congress of more crypto-friendly lawmakers.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 20, 2024 15:12 ET (20:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.